Neurosurgical and neurological research is used to treat and save the lives of children and adults living with life threatening medical conditions.
Donations allow the funding of world class medical research into the cause, diagnosis, prevention and treatment of disease and injury of the brain, spine and nervous system.
The Neurosurgical Research Foundation Inc. was formed in 1963 and was the first of its kind in Australia. The objective of the Foundation is directed towards funding research into the cause, diagnosis, prevention and treatment of disease, injuries or malfunction of the brain, spine and nerves.
Key Areas of Research
Neuroscience researchers are looking for ways to improve treatments which can save lives of children and adults living with these neurosurgical and neurological conditions.
Click here to donate to General Neurosurgical Research.
Much of the death and disability of tumours is attributable to their ability to spread and invade the brain leading to devastating consequences such as brain swelling. Brain cancer kills more adults under 40 than any other cancer, kills more children than any other disease, and takes one life about every seven hours in Australia. Brain Tumour Research at the NRF is aimed at improving treatments, reducing cancer invasiveness, impeding tumour growth and enhancing the surgical response to prolong survival and improve quality of life.
Brain Tumour Research:
Prof Stuart Pitson's research team is examining more effective chemotherapy treatment for one of the most lethal brain cancers, Glioblastoma.
Kimberley Mander has developed a system that artificially replicates part of the barrier that separates our brain from our bloodstream. When cancers around the body spread to the brain, they unlock this barrier and squeeze through. Kim's work focusses on locking down the barrier, stopping metastasis in its tracks, using a targeted drug treatment. Secondary Brain Tumours
Stefan Court-Kowalski's Research focusses on tumours that originate in the brain, again using a highly specialised drug that will reduce the tumours' ability to grow and invade surrounding healthy brain. Primary Brain Tumours
Click here to donate to Brain Tumour Research.
Over 72,000 Australians suffer a stroke each year, 2/3 of which are left dead or disabled as a result.
The stroke research team, led by Dr Renée Turner, is using novel, pre-clinical models to map the development of brain swelling and changes in brain pressure following stroke in order to develop targeted and more effective treatments to reduce the devastating morbidity and mortality associated with these conditions.
Annabel Sorby-Adams research is looking at that brain swelling and increased brain pressure which are the leading causes of death and disability in the first week following stroke. Annabel’s investigations will examine the effect of a treatment, the NK1 tachykinin receptor antagonist and whether it can prevent the development of brain swelling and life threatening elevations in brain pressure.
Click here to donate to Stroke Research.
Neurosurgery saves children's lives every day. Medical research saves children's lives in the future.
The NRF is managing this Paediatric Appeal to raise the $2 million to establish this life-saving research to save children's lives.
How will the funds be used?
Research into brain disease and injury in children will be the primary focus of this appeal. The position will be based in Adelaide in conjunction with the University of Adelaide, Royal Adelaide Hospital, and Women's & Children's Hospital. At present, children die every day or their lives are destroyed through conditions such as:
The Paediatric Appeal will fund lifesaving research into these deadly, life destroying conditions and diseases.
Key Areas of Expenditure
Click here to donate to The Paediatric Appeal.
Traumatic Brain injury (TBI) is the leading cause of disability and death worldwide and is associated with significant impairment in brain function, impacting cognitive, emotional, behavioural and physical functioning. It is estimated that as many as 54-60 million people worldwide suffer from a TBI each year. While the acute effects of TBI are well characterized, a significant number of people affected by TBI develop long-lasting neuropsychiatric and cognitive impairments. TBI is also a significant risk factor for later development of dementia and Parkinson’s disease, although the brain mechanisms behind this association are still poorly understood.
It is estimated that between 54 and 60 million people worldwide suffer from a TBI each year.
Spinal Cord Injury (SCI) leaves patients disabled and dependent for basic daily activities. There are currently no effective treatments available for SCI and novel therapies are urgently required to reduce such devastating disability.
Spinal Cord Injury Research:
Dr Anna Leonard’ research is targeting raised pressure within the spinal cord after a traumatic spinal cord injury. Future studies will focus on increasing the space in which the spinal cord exists to accommodate for its increased volume due to swelling. This will alleviate the subsequent pressure increase, promoting tissue survival and reducing functional deficits.
Traumatic Brain Injury Research:
Dr Lyndsey Collins-Praino: While the acute effects of traumatic brain injury (TBI) are well-known, a number of individuals affected by TBI also develop chronic problems such as depression and cognitive impairment. Although the brain mechanisms of these impairments are currently unclear, persistent inflammation in the brain may play a key role.
Our current NRF-funded research projects investigate whether reducing brain inflammation immediately after injury can improve long-term outcomes in an experimental model of TBI. This work may have important consequences for the prevention of neurodegenerative diseases, such as dementia.
Stephanie Plummer is investigating a peptide derived from the amyloid precursor protein(app), as a novel therapeutic agent against traumatic brain injury. Our recently published series of studies convincingly demonstrates that a protein found naturally within the brain cells, the amyloid precursor protein (APP), has a protective role against TBI. We, in collaboration with our colleagues at the University of Melbourne who are experts in APP biology, have also identified the specific region in APP that is responsible for this protective activity. Our work has established APP to be a viable and novel therapeutic agent for treating TBI. We now plan to improve the protective activity of APP in order to make it a better therapeutic molecule for the treatment of TBI.
Neurodegenerative diseases are diseases associated with both the abnormal build-up of toxic aggregates of protein and the death of neurons (brain cells) in particular areas of the brain. This class of diseases includes multiple conditions, but the two most common are dementia and Parkinson’s disease (PD).
Dementia is the second leading cause of death in Australia. There are more than 413,106 Australians living with dementia, with one new case diagnosed every 6 minutes. Alzheimer’s disease is the most common form of dementia, affecting up to 70% of all people with dementia. Without a medical breakthrough soon, the number of Australian with dementia is expected to soar to more than 900,000 by 2050.
Parkinson’s disease is also a significant issue, both here in Australia and throughout the world. There are currently 8-10 million cases of PD worldwide. In Australia alone, there are more than 70,000 cases, with PD affecting 1 in every 340 Australians. Given our rapidly ageing population, this number is expected to double by 2030. PD currently costs the Australian economy more than $1.1 billion each year!
Currently, there are no treatments to stop the progression of neurodegenerative diseases, with available options only providing some relief from the symptoms of these conditions. Before a cure can be developed, it is critical that we understand more about the factors that can lead to the development of neurodegeneration.
Neurodegenerative Disease Research:
Dr Lyndsey Collins-Praino, is investigating how brain inflammation changes over time, and whether this is associated with brain changes characteristic of neurodegenerative diseases, such as Alzheimer’s and Parkinson’s disease. One major risk factor for these diseases is traumatic brain injury (TBI). While it is not yet clear how TBI can lead to the brain changes seen in PD, often decades after the original injury, TBI is known to be associated with the induction of significant inflammation in the brain. This may set the stage for the later emergence of neurodegenerative disease. This raises the exciting possibility that targeting inflammation after injury may help to reduce the incidence of these conditions, at least in a subset of the population.
Dr Collins-Praino is also focused on understanding the brain mechanisms that underlie cognitive impairments, such as memory problems and difficulties with planning and paying attention, in these conditions.
Dr Emma Thornton is the only researcher in the world who has identified that substance P plays a role in dopamine cell death in Parkinson’s disease (PD). In PD, dopamine levels decrease due to a slow and progressive death of brain cells. It is critical for the treatment of PD to target this cell death When we block its action with an antagonist, we protect dopamine cells and restore brain function. Testing this discovery in patients is in progress.
Neurodegeneration Concussion Research:
Neurodegeneration Concussion: An especially common injury in contact sports such as football, chronic traumatic encephalopathy is a neurodegenerative disease, which appears to be exclusively related to repeated concussion.
Dr Francis Corrigan Chronic Traumatic Encephalopathy (CTE) is a neurodegenerative disease which appears to be exclusively related to repeated concussion. This research considers the mechanisms by which systemic inflammation accelerates the disease process, leading to neuronal cell death.
Dr Francis Corrigan’s research examines how concussion – particularly repeated concussion – may increase the risk of developing cognitive deficits later in life. Previous research has suggested that levels of substance P (SP) are higher in adolescents and thus they may have a greater inflammatory response to a concussive insult than an adult. We will be investigating whether blockade of this inflammatory response – by preventing the actions of SP – will prevent the development of cognitive deficits following concussion in adolescence.